Universität zu Köln

Brockelmann, Paul J., von Tresckow, Bastian and Engert, Andreas (2022). Novel therapeutic approaches in relapsed or refractory Hodgkin lymphoma. Onkologie, 28 (10). S. 901 - 908. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Full text not available from this repository.

Abstract

Background While classical Hodgkin lymphoma (HL) is curable in most cases with risk-adapted first-line therapy, the treatment of patients with relapsed or primary refractory (r/r) HL in particular remains a challenge. Methods This review article discusses the currently available data on the safety and efficacy of newer therapeutic approaches for r/r HL from a practice-oriented perspective. Results In patients suitable for intensified therapy, durable remission can be achieved in approximately 50% of cases with polychemotherapy-based salvage followed by high-dose chemotherapy with autologous stem cell transplantation (ASCT). With the approval of targeted agents, even multiply relapsed, refractory, elderly, or multimorbid patients now have multiple treatment options. In addition to the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV), the two anti-PD1 antibodies nivolumab and pembrolizumab are increasingly being used here as immune checkpoint inhibitors. The anti-PD1 antibodies are also used in earlier lines of therapy, e.g., significantly longer progression-free survival (PFS), was achieved with pembrolizumab in an international phase III trial compared to BV with comparable response rates. The therapeutic landscape of r/r HL is rapidly changing and additional promising targeted agents such as the antibody-drug conjugate camidanlumab tesirine, different checkpoint inhibitors, and anti-CD30 CAR T cells are currently being tested in trials. Conclusions Rational use of available therapeutic approaches is expected to improve the prognosis of patients with multiple r/r HL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Brockelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-664479
DOI:	10.1007/s00761-022-01172-1
Journal or Publication Title:	Onkologie
Volume:	28
Number:	10
Page Range:	S. 901 - 908
Date:	2022
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	2731-7234
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; OPEN-LABEL; FOLLOW-UP; SINGLE; CHEMOTHERAPY; MULTICENTER; NIVOLUMAB Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66447